Losing Traction in Session: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

Dsuvia is for the management of acute pain in trauma and ambulatory settings

Dsuvia is for the management of acute pain in trauma and ambulatory settings

Bridgeway Cap Mgmt holds 0.01% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 319,150 shares. Edwards now owns $355,200 of stock as reported to the SEC.

EX-99.1 2 ex_96542.htm EXHIBIT 99.1 ex_96542.htm Exhibit 99.1 Press Release AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA REDWOOD CITY, ... Meeder Asset Management stated it has 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Looking at the stock's movement on the chart, AcelRx Pharmaceuticals, Inc. recorded a 52-week high of $5.75. The volume of 3.14 Million shares climbed up over an trading activity of 1.63 Million shares. The 1-year high was reported on Oct, 12 by Barchart.com.

In the transaction dated August 24, 2017, the great number of shares acquired came courtesy the Director; Edwards Mark G added a total of 5,000 shares at an average price of $3.02, amounting to approximately $15,100. Its pivot point high generated sell signal on Tuesday October 10, 2017, which calls for additional declines until the stock forms a new pivot point low, as this could be a buying opportunity. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The NASDAQ listed company saw a recent bid of 2.35 and 13811028 shares have traded hands in the session. Caesarstone Ltd (NASDAQ:CSTE) has risen 6.39% since October 11, 2016 and is uptrending. It has underperformed by 30.94% the S&P500. Its minimum price target estimates has been figured out at $3 while the maximum price target forecast is established at $12.5. Analysts expect next quarter's EPS will be $-0.25 with next year's EPS projected to be $-0.84. The analysts estimated EPS for the higher end at -0.19 and lower end at -0.29 while the year ago reported earnings per share was -0.22. Therefore 75% are positive.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $7.1 on the stock, this valuation is based on 5 number of opinions. Caesarstone Sdot-Yam had 23 analyst reports since August 6, 2015 according to SRatingsIntel. The median estimate represents a 34.62% increase from the last price of 5.20. Da Davidson And has 0% invested in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 61,900 shares.

AcelRx Pharmaceuticals, Inc. (ACRX) now the company's industry has 13.86 P/E and the sector P/E is 16.24. The firm has "Buy" rating by H.C. Wainwright given on Tuesday, May 3.

Malaga Cove Capital, LLC expanded its investment by buying 2,900 shares an increase of 28.3% from 03/31/2017 to 06/30/2017. Cowen & Co maintained the stock with "Hold" rating in Tuesday, August 1 report. (ACRX) in the open market.

The rejection was clearly disappointing and approval had been seen as likely, given the lack of a committee meeting, RBC Capital Markets analyst Randall Stanicky said in a client note. Given the stock's recent action, it seemed like a good time to take a closer look at the company's recent data.

AcelRx Pharmaceuticals, Inc.is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The third largest holder is Palo Alto Investors, Llc, which now holds $5.37 million worth of this stock and that ownership represents almost 2.08% of its market capitalization. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.